Understand the source comparison
SS-31 vs Other Mitochondrial Peptides: Performance Comparison
Before assuming SS-31 has failed, compare its mechanism against alternative mitochondrial-targeting compounds to confirm you're using the right tool for your research question. SS-31 (Elamipretide) Cardiolipin binding; cristae stabilisation; reduced ROS at Com
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Before assuming SS-31 has failed, compare its mechanism against alternative mitochondrial-targeting compounds to confirm you're using the right tool for your research question.
- SS-31 (Elamipretide)
- Cardiolipin binding; cristae stabilisation; reduced ROS at Complex I/III
- 24–48 hours
- 14 days at 2–8°C
- Acute mitochondrial stress models; ischemia-reperfusion; oxidative damage
- Best for targeted mitochondrial membrane protection. Highly effective but requires perfect handling
- MOTS-c
- Mitochondrial-derived peptide; AMPK activation; insulin sensitivity
- 3–5 days
- 21 days at 2–8°C
- Metabolic dysfunction models; aging research
- Broader metabolic effects but slower onset than SS-31
- Humanin
- Mitochondrial-encoded cytoprotective peptide; BAX inhibition
- 48–72 hours
- 10 days at 2–8°C
- Apoptosis models; neurodegenerative research
- Complementary to SS-31 for anti-apoptotic signaling
- NAD+ Precursors (NMN/NR)
- NAD+ replenishment; sirtuin activation
- 7–14 days
- N/A (oral stable)
- Chronic metabolic research; aging
- Indirect mitochondrial support. Not membrane-specific like SS-31